Tipifarnib shows promise in refractory HRAS-mutant urothelial carcinoma
Treatment with tipifarnib appears to be safe with favourable efficacy in patients with treatment-refractory urothelial carcinoma harbouring HRAS mutations, according to the results of a phase II trial.
Tipifarnib shows promise in refractory HRAS-mutant urothelial carcinoma
27 Oct 2020
